235 related articles for article (PubMed ID: 8004607)
41. [Retrospective analysis of 108 ductal carcinomas in situ of the breast treated by radiosurgery association].
Fourneret P; Artignan X; De Cornulier J; Pasquier D; Panh MH; Payan R; Kolodié H; Vincent F; Fric D; Bernard P; Colona M; Bolla M
Cancer Radiother; 2006 Dec; 10(8):550-8. PubMed ID: 16890006
[TBL] [Abstract][Full Text] [Related]
42. Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast.
Hillner BE; Desch CE; Carlson RW; Smith TJ; Esserman L; Bear HD
J Clin Oncol; 1996 Jan; 14(1):70-7. PubMed ID: 8558224
[TBL] [Abstract][Full Text] [Related]
43. [Morphology and contrast enhancement of ductal carcinoma in situ in dynamic 1.0 T MR mammography].
Sittek H; Kessler M; Heuck AF; Bredl T; Perlet C; Künzer I; Lebeau A; Untch M; Reiser M
Rofo; 1997 Sep; 167(3):247-51. PubMed ID: 9376552
[TBL] [Abstract][Full Text] [Related]
44. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study.
Collins LC; Tamimi RM; Baer HJ; Connolly JL; Colditz GA; Schnitt SJ
Cancer; 2005 May; 103(9):1778-84. PubMed ID: 15770688
[TBL] [Abstract][Full Text] [Related]
45. Three-dimensional RODEO breast MR imaging of lesions containing ductal carcinoma in situ.
Soderstrom CE; Harms SE; Copit DS; Evans WP; Savino DA; Krakos PA; Farrell RS; Flamig DP
Radiology; 1996 Nov; 201(2):427-32. PubMed ID: 8888235
[TBL] [Abstract][Full Text] [Related]
46. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).
Hwang ES; Hyslop T; Lynch T; Frank E; Pinto D; Basila D; Collyar D; Bennett A; Kaplan C; Rosenberg S; Thompson A; Weiss A; Partridge A
BMJ Open; 2019 Mar; 9(3):e026797. PubMed ID: 30862637
[TBL] [Abstract][Full Text] [Related]
47. [Ductal carcinoma in situ of the breast].
Barth A; Köchli OR; Brenner RJ; Giuliano E; Castiglione M
Schweiz Med Wochenschr; 1995 Jan; 125(4):103-12. PubMed ID: 7878398
[TBL] [Abstract][Full Text] [Related]
48. Ductal Carcinoma in Situ: State-of-the-Art Review.
Grimm LJ; Rahbar H; Abdelmalak M; Hall AH; Ryser MD
Radiology; 2022 Feb; 302(2):246-255. PubMed ID: 34931856
[TBL] [Abstract][Full Text] [Related]
49. Management of breast ductal carcinoma in situ in Catalonia, Spain: Results from the Grup Oncologic Calalà-Occità-Catalonia survey with 9-year follow up.
Cambra MJ; Farrús B; Moreno F; Anglada L; Arenas M; Ballester R; Casals J; Cusidó M; García V; Gutiérrez C; Mollà M; Pedro A; Reyes V; Sanz X
Breast; 2017 Oct; 35():196-202. PubMed ID: 28806663
[TBL] [Abstract][Full Text] [Related]
50. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
Sakorafas GH; Tsiotou AG
Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
[TBL] [Abstract][Full Text] [Related]
51. [Standards, Options and Recommendations for the management of ductal carcinoma in situ of the breast (DCIS): update 2004].
Cutuli B; Fourquet A; Luporsi E; Arnould L; Caron Y; Cremoux Pd; Dilhuydy JM; Fondrinier E; Fourme E; Giard-Lefevre S; Blanc-Onfroy ML; Lemanski C; Mauriac L; Sigal-Zafrani B; Tardivon A; This P; Tunon de Lara C; Kirova Y; Fabre N;
Bull Cancer; 2005 Feb; 92(2):155-68. PubMed ID: 15749645
[TBL] [Abstract][Full Text] [Related]
52. The consequence of undertreatment of patients treated with breast conserving therapy for ductal carcinoma in-situ.
Lee DY; Lewis JL; Wexelman BA; Freedman BC; Ross RE; Tartter PI
Am J Surg; 2013 Nov; 206(5):790-7. PubMed ID: 23866765
[TBL] [Abstract][Full Text] [Related]
53. Pathobiology of breast cancer--treatment implications.
Vorherr H
Eur J Obstet Gynecol Reprod Biol; 1984 May; 17(2-3):219-35. PubMed ID: 6329835
[TBL] [Abstract][Full Text] [Related]
54. Cytological criteria for the diagnosis of intraductal hyperplasia, ductal carcinoma in situ, and invasive carcinoma of the breast.
Bofin AM; Lydersen S; Hagmar BM
Diagn Cytopathol; 2004 Oct; 31(4):207-15. PubMed ID: 15452908
[TBL] [Abstract][Full Text] [Related]
55. The role of excision and surveillance alone in subclinical DCIS of the breast.
Schwartz GF
Oncology (Williston Park); 1994 Feb; 8(2):21-6; discussion 26-7, 31-2, 35. PubMed ID: 8167086
[TBL] [Abstract][Full Text] [Related]
56. Heterogeneity of ductal carcinoma in situ of the breast.
Lagios MD
J Cell Biochem Suppl; 1993; 17G():49-52. PubMed ID: 8007709
[TBL] [Abstract][Full Text] [Related]
57. Ductal carcinoma in situ of the breast.
Frykberg ER; Masood S; Copeland EM; Bland KI
Surg Gynecol Obstet; 1993 Oct; 177(4):425-40. PubMed ID: 8211592
[TBL] [Abstract][Full Text] [Related]
58. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?
Lakhani SR; Audretsch W; Cleton-Jensen AM; Cutuli B; Ellis I; Eusebi V; Greco M; Houslton RS; Kuhl CK; Kurtz J; Palacios J; Peterse H; Rochard F; Rutgers E;
Eur J Cancer; 2006 Sep; 42(14):2205-11. PubMed ID: 16876991
[TBL] [Abstract][Full Text] [Related]
59. Treatment of ductal carcinoma in situ: an uncertain harm-benefit balance.
Prescrire Int; 2013 Dec; 22(144):298-303. PubMed ID: 24600734
[TBL] [Abstract][Full Text] [Related]
60. Ductal carcinoma in situ. Part I: Definition and diagnosis.
Delaney G; Ung O; Bilous M; Cahill S; Greenberg M; Boyages J
Aust N Z J Surg; 1997; 67(2-3):81-93. PubMed ID: 9068547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
